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ABSTRACT
Irritable bowel syndrome (IBS) is a common disorder of the lower gastrointestinal tract. The 
pathophysiology is far from settled, but a gut microbial dysbiosis is hypothesized to be 
a contributing factor. We earlier published a randomized double-blind placebo-controlled clinical 
trial on fecal microbiota transplantation (FMT) for IBS – the REFIT trial. The present data set 
describes the engraftment and includes participants from the study who received active FMT; 14 
participants with effect of FMT (Effect) and 8 without (No effect). Samples were collected at baseline, 
after 6 and 12 months. Samples from the transplants (Donor) served as a comparator. In total 66 
recipient samples and 17 donor samples were subjected to deep metagenomic sequencing, and 
taxonomic and functional analyses were performed. Alpha diversity measures showed 
a significantly increased diversity and evenness in the IBS groups compared to the donors. 
Taxonomic profiles showed higher relative abundance of phylum Firmicutes, and lower relative 
abundance of phylum Bacteroidetes, compared to donors at baseline. This profile was shifted 
toward the donor profile following FMT. Imputed growth rates showed that the resulting growth 
pattern was a conglomerate of donor and recipient activity. Thirty-four functional subclasses 
showed distinct differences between baseline samples and donors, most of which were shifted 
toward a donor-like profile after FMT. All of these changes were less pronounced in the No effect 
group. We conclude that FMT induces long-term changes in gut microbiota, and these changes 
mirror the clinical effect of the treatment. The study was registered in ClinicalTrials.gov 
(NCT02154867).
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Background
Irritable bowel syndrome (IBS) is a functional gut 
disorder characterized by abdominal pain or dis-
comfort associated with abnormal frequency and 
consistency of bowel movements. IBS presents as 
one of the three phenotypes: IBS with diarrhea 
(IBS-D), constipation (IBS-C), or mixed (IBS-M). 
IBS is a very common complaint with an estimated 
global prevalence of 11.2%, but higher in Northern 
Europe, and more frequent among young women 
than in men.1
A key challenge in IBS research is that the patho-
physiology is largely unknown, and remains contro-
versial. Interaction between host and gut microbiota 
is considered a new clinical frontier. Experimental 
evidence and theoretical considerations imply that 
disturbances in this interaction may have multiple 
effects as diverse as obesity, metabolic syndrome, 
liver cirrhosis, inflammatory bowel disease, and color-
ectal cancer.2 The current hypothesis on IBS patho-
physiology focuses on the interaction between gut 
microbiota and host factors such as immune system 
activation, altered neuroendocrine signaling, and gut 
mucosal barrier function.3 This hypothesis is sup-
ported by the notion that IBS-like traits can be 
observed in rats following fecal transplant from IBS 
patients.4
Both diet regimens (low intake of fermentable 
oligo-, di-, and monosaccharides and polyols 
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(low-FODMAP); low fructose; gluten-free), food 
supplements (soluble fiber, peppermint oil), pro-
biotics, and pharmacologic treatments (e.g., pros-
taglandin analogs, 5HT3 antagonists, 
antispasmodics, and antibiotics) are available 
treatments of IBS. However, the drugs with best 
documentation show low to moderate effect, and 
the dietary interventions have not been evaluated 
extensively.3,5 In Europe, the agreed intervention 
of choice is in general dietary interventions, like 
low FODMAP.6 Documentation of its efficacy is, 
however, relatively poor, 7 and the theoretical 
framework is not completely understood. 
Several mechanisms of action have been sug-
gested including both microbial shifts in profile 
and metabolic output, and changes in the intest-
inal regulatory systems like serotonin-producing 
cells (reviewed by Staudacher and Whelan8).
It has been hypothesized that a dysbiosis of the 
gut flora is an important part of the pathophysiology 
of IBS.9,10 This is supported by the finding of 
a distinctly different metagenomic stool profile in 
a large case-control study on IBS vs healthy controls 
(and inflammatory bowel disease).11 Consequently, 
altering the gut microbiome by fecal microbiota 
transplantation (FMT) has been suggested as 
a possible treatment option in IBS.12–14
Our previously published REFIT trial provided the 
first proof of concept for FMT in IBS patients.15 It 
included 90 IBS patients in a randomized double- 
blind placebo-controlled clinical trial of donor FMT 
vs. placebo in a 2:1 randomization. Patients with IBS- 
D or IBS-M defined by the ROME III criteria, scored 
as moderate to severe according to the IBS severity 
scoring system (IBS-SSS), were enrolled locally by 
general practitioners in northern Norway. The 
donor feces was freshly processed, and was used the 
same day, or frozen for later use. The participants’ 
own preprocessed and frozen feces served as placebo. 
The transplant was administered by a colonoscope to 
the cecum. The main outcome measure was self- 
rated clinical effect assessed by the IBS-SSS (reduc-
tion of >75 points). The trial showed significant 
clinical effects 3 months after administration of 
FMT, with very few and minor self-limited adverse 
effects until 1 year post-FMT.
However, the effect of FMT in IBS is contested, as 
not all studies agree on its efficacy.16 The mode of 
delivery may be a key issue, as classic FMT shows 
promise, while capsule delivery does not.17 In order to 
understand this observed variability, it is necessary to 
characterize the intervention of classic FMT in detail.
Here, we provide a data set generated by deep 
metagenomic sequencing of fecal samples collected 
before and after FMT during the REFIT trial.
Results
Stool was collected at three time points from the 83 
participants who completed the REFIT study. The pre-
sent data set was constructed to investigate the effects of 
engraftment of the donor transplant; hence, we picked 
only participants from the active treatment group who 
received donor transplants. Only 22 participants with 
complete sample sets were available due to low compli-
ance in delivery of fecal samples after the treatment. Of 
these, 14 had good effect (termed Effect), and 8 had none 
or only a transient effect of the intervention (termed No 
effect). Seventeen samples from the transplants (termed 
Donors) used for treatment of the 22 participants, from 
two individual donors, acted as comparator group in the 
present setup. The baseline characteristics for the 
selected study participants are presented in Table 1. At 
baseline, no significant differences in patient character-
istics were detected between the IBS groups.
Alpha diversity
Measures of diversity and evenness are presented in 
Figure 1(a). The richness (Chao1 and Observed) 
was significantly higher in the Effect group than in 
the Donors at all time points (P = .0002; 0.0002; 
0.0012 for baseline, 6 months, and 12 months, 
respectively, for Observed). The No effect group 
had significantly lower richness at baseline 
(P = .0049 for Observed) compared to the Effect 
group, with values comparable to the Donors 
(P = 1.0000 for Observed). At 12 months, the rich-
ness in the No Effect group increasingly resembled 
that of the Effect group (P = 1.0000 for Observed). 
However, looking at diversity measures that 
include evenness (Shannon and Simpson), both 
IBS participant groups showed higher diversity at 
baseline compared to the Donors (P = .0026 and 
0.0046 by Simpson index for Effect and No effect 
groups, respectively), and these measures did not 
change significantly with time.
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Figure 1. Panel A: Box plots with alpha diversity estimates where each sub-panel shows a different type of estimator. The colors group 
the samples into seven groups, and each point represents the richness estimate per sample. The data was filtered so that taxa 
occurring < five times in at least 20% of the samples were excluded from the analysis. Panel B: nMDS ordination plots using Bray-Curtis 
distance between samples. Comparisons of the Effect group at baseline, after 12 months and the donor samples are visualized separate 
from the No effect group at baseline, after 12 months and the donor samples. The data were filtered so that taxa with a mean fractional 
abundance < 10−5 were excluded from the analysis.
Table 1. Baseline characteristics. Key characteristics of the participants in the present data set. P values generated by Mann–Whitney 
for continuous variables, and Fischer’s Exact Test for categorical variables.
Donor 
(n = 2) Effect of FMT (n = 14) No effect of FMT (n = 8) P
Age mean (range) 18 47 (19–69) 49 (30–70) 0.87
Sex F/M 0/2 10/4 6/2 1.00
Body mass index (kg/m2; median (range)) n/a 24.8 (21.3–41.2) 25.7 (19.6–33.6) 0.94
IBS-D/IBS-M n/a 9/5 4/4 0.66
IBS-SSS mean (95%CI) n/a 271 (239–303) 259 (210–308) 0.62
Years w IBS mean (95%CI) n/a 16 (9–23) 14 (1–27) 0.48
FODMAP intake mean g/day (95%CI) n/a 13 (6–20) 11 (2–20) 0.71
Fresh/frozen transplant n/a 7/7 6/2 0.38
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Beta diversity
Non-metric multidimensional scaling (NMDS) was 
performed on beta diversity in the fecal samples 
from the Donor, Effect, and No Effect groups prior 
to FMT and after 12 months (Figure 1(b), left 
panel). A clear separation between Donor and 
Effect samples was found at both time points. 
While the microbial composition of fecal samples 
from the Effect group, after 12 months, clustered 
closer to the Donor samples, the No effect samples 
did not show any separation in clustering between 
the sampling time points (Figure 1(b), right panel).
Relative taxonomic abundances
The taxonomic profiles of the Donor and IBS 
patient samples were widely different (Figure 2(a); 
only phylum is shown). The Donor samples had 
a relatively higher abundance of Bacteroidetes 
than the patient samples, and lower abundance of 
Figure 2. Panel A: Relative abundance of the most prevalent phyla for the seven groups. The data were filtered so that taxa not seen 
more than 5 times in at least 20% of the samples in the total dataset were removed. Following this, only taxa with a mean greater than 
10−5 (fractional abundance > 0.00001) were kept before agglomeration at phylum level. Panel B: Differential abundance calculated 
with DESeq2 at phylum and family level, in the Effect group, 12 months vs. baseline. Positive log2FC indicate enriched taxa after FMT, 
negative log2FC indicate decreased taxa after FMT. Families indicated on the X-axis are colored according to phyla. FDR cut off for 
inclusion in the plot was < 10−4.
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Firmicutes and Actinobacteria. The relative abun-
dance profiles changed over the sampling period in 
both the Effect and No effect groups, becoming 
more similar to the Donor profile with increased 
abundance Bacteroidetes and a reduction of 
Firmicutes. For the No effect group, however, the 
6 month samples, in particular, had relatively low 
abundance of Bacteroides and relatively high abun-
dance of Actinobacteria.
Differential abundance
In order to identify taxa that changed significantly 
in the Effect group, from baseline to 12 months, the 
data set was subjected to an unsupervised differen-
tial abundance analysis using differential gene 
expression based on the negative binomial distribu-
tion (DESeq2) (Figure 2(b), S1). At baseline, prior 
to FMT, species belonging to the phyla Firmicutes, 
Actinobacteria, Proteobacteria (seven different spe-
cies), and Verrumicrobia were more abundant. 
Twelve months after FMT a higher abundance of 
species belonging to the phyla Bacteroidetes and 
Proteobacteria was found (23 different species) of 
which species belonging to the Bacteroidetes was 
particularly more abundant.
In total, 170 species showed a significantly dif-
ferent abundance in response to FMT (false discov-
ery rate (FDR) <0.01 and log2fold change <-2 or 
>2) (Table S1); of these, 128 species increased in 
abundance and 42 decreased in abundance after 
FMT. Twenty-four of the 36 species belonging to 
the Firmicutes phylum showed a reduced abun-
dance following FMT (66% of Firmicutes; 14% of 
170). In phylum Bacteroidetes, 64 of 67 species 
increased in abundance after FMT (96% of 
Bacteroidetes; 38% of 170). Of species known to 
be involved in the production of short-chain fatty 
acids (SCFA), 3 of 4 Eubacterium sp., 0 of 2 
Clostridium sp., 11 of 12 Ruminococcus sp., 2 of 2 
Klebsiella sp., and 2 of 2 Lactobacillus sp. had 
a decreased abundance after FMT. However, con-
sidering baseline counts of these species, the result-
ing SCFA production capacity (based on mean 
baseline counts by fold change) increased by 
a factor 6.7 after FMT. Akkermansia muciniphila 
had a significantly reduced abundance at 
12 months.
Multivariate regression model of the taxonomic 
analysis
The orthogonal partial least squares projection to latent 
structures (OPLS) analysis showed that the taxonomic 
profile in the Effect group moved toward the Donor 
profile over time after FMT treatment. At 12 months, 
however, the profiles were still clearly distinct. Notably, 
the most profound change was observed between base-
line and 6 months after the FMT treatment, Figure 3(a). 
From the OPLS model, a shortlist of the 50 most impor-
tant species affecting the shift in taxonomy profile over 
time was generated based on regression coefficients, 
Figure 3(b). The list shows that 7 species decreased 
after treatment (3 Firmicutes, 2 Actinobacteria, and 2 
Proteobacteria), and 25 increased (18 Bacteroidetes, 3 
Firmicutes, 2 Proteobacteria, and 2 Actinobacteria).
Growth rate dynamics
Growth rates for bacterial species identified in the 
Donor samples, and from the Effect group prior to 
treatment and after 12 months, were estimated using 
the growth rate index (GRiD).18 In total, GRiD 
reported 959 species for the 47 samples. After filtering 
of low-frequent species (occurring <15 times in <30 
samples), and including only species with an FDR < 
0.00005, we identified 27 species that displayed 
a significantly different growth rate in the three 
groups, Figure 4. The majority of these species were 
in the lag or stationary phase prior to FMT but were in 
exponential growth phase both in the Donor samples 
and in samples taken after FMT. The largest group of 
species found were belonging to the phylum 
Bacteroidetes (15/27), followed by different species of 
the phylum Firmicutes (8/27), among these 
Coprococcus catus, a known butyrate producer.
Functional analysis
In total, 34 functional subsystems (SEED; please see 
the Methods section) showed a significant differen-
tial abundance in samples from the Effect group 
after 12 months, compared to the corresponding 
baseline samples (Figure 5). Thirteen functional 
subsystems were significantly less abundant after 
FMT (13/34 – 38.2%), while 21 were significantly 
more abundant after FMT. The subsystem Fructose 
and Mannose inducible PTS, involved in sugar 
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transport, showed the largest decrease in abun-
dance of all subsystems after FMT. The Inorganic 
sulfur assimilation subsystem and the Heme and 
hemin uptake and utilization systems in Gram posi-
tives were both significantly less abundant. Acetyl- 
CoA fermentation to butyrate was less abundant at 
baseline, however not significantly so. Two func-
tional subsystems involved in Menaquinone, K2 
biosynthesis, and two subsystems involved in 
uptake of Zinc and Manganese in addition to the 
tetrahydrofolate biosynthesis pathway were 
significantly more abundant at 12 months post- 
FMT. The subsystem CBSS-498211.3.peg.1514, 
with function unknown, showed the largest change 
of all at 12 months post-FMT.
We then calculated individual differences in relative 
abundance between Donors and recipients (baseline 
sample vs. Donor sample used for each participant), as 
well as individual changes (12 months vs. baseline) in 
each of the 34 functional classes, for each participant. 
The baseline differences between Donors and recipi-
ents were quite similar in Effect and No effect groups 
Figure 3. Multivariate regression analysis of the bacterial species. Each sample was labeled according to the corresponding study 
group. Panel A: This t1/t2-score plot of the orthogonal partial least squares projection to latent structures (OPLS) model (one predictive 
component and one orthogonal component) was built from the bacterial species composition in stool samples taken from the Donors, 
and from the Effect group at 3 time points: baseline, 6, and 12 months after FMT. The performance parameters R2Xcum, R2Ycum and 
Q2cum were 0.36, 0.61 and 0.32, respectively. Panel B: The top 50 bacterial species ranked by regression coefficients pertaining to the 
predictive components. To make the coefficients readily comparable, the independent variables for different taxa were scaled and 
centered prior to the analysis. The error bars indicate the confidence intervals of the coefficients. The coefficient is considered 
significant (above noise level), when the confidence interval does not include zero. Significant features are color-coded according to 
phylum.
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(Figure S2, panel A). At 12 months, however, conver-
gence toward the Donor profile was more profound in 
the Effect group than in the No effect group (Figure S2, 
panel B). Notably, Carbohydrates was the only func-
tional class with a positive change in the Effect group, 
which could not be found in the No effect group. 
However, this difference was not significant. 
A further sub-analysis focused on the Carbohydrates 
cluster revealed subtle differences in systems involved 
in D-Galacturonate and D-Glucuronate utilization, 
D-ribose utilization, L-rhamnose utilization, Lactose 
and Galactose uptake and utilization, and Lactose uti-
lization (Figure S3). Next, a multivariate regression 
model of the functional level 3 classes was built. 
Overall, the OPLS model (Figure 6(a)) showed the 
same movement from baseline toward Donor profile 
during the time course, though not as clearly as seen in 
the taxonomic regression model (Figure 3(a)). Eleven 
functional subsystems showed significant changes fol-
lowing FMT, these were pathways associated with 
Acetyl-CoA fermentation, inorganic sulfur assimila-
tion, transport of Zinc, and heme biosynthesis orphans 
(Figure 6(b)).
Discussion
We have performed deep metagenomic sequencing of 
a selection of samples from our previously published 
randomized clinical trial on FMT vs placebo for non- 
constipated IBS. We found that alpha diversity was 
higher in stool from IBS subjects than in stool from 
the Donors. For subjects who experienced an effect of 
the treatment, a trend of convergence toward the Donor 
microbiome profile after FMT was shown; this trend 
Figure 4. Growth rate score (GRiD) of the most frequent occurring species for samples in: (a) No effect group at baseline (green), after 
12 months (purple) and the Donor samples (cyan); and (b) Effect group at baseline (pink), after 12 months (blue) and the Donor samples 
(cyan). GRiD score > 1 is an indication of bacteria in the growth phase, while GRiD score < 1 indicates bacteria in stationary or lag 
phase. The data were filtered so that species occurring < 15 times in < 30 samples were excluded from the analysis. FDR cut off for 
inclusion in the heat map was < 0.00005.
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was however less clear for subjects with no treatment 
effect. This trend was seen both on the taxonomic and 
on the functional level by the dimension reduction 
analysis and was even more clearly demonstrated by 
the multivariate regression (OPLS) models. Selected fea-
tures on the phyla level, such as the fraction of 
Bacteroidetes and Firmicutes, showed the same trend 
(Figure 1(a) and (b)).
Taxonomy
Compared to Donor samples, the baseline profile of IBS 
patients found in the present data set shows a relative 
dominance of Firmicutes over Bacteroidetes, while 
Donor samples show the opposite pattern. This finding 
supports an earlier report using similar methodology, 11 
and some studies using 16S ribosomal ribonucleic acid 
(16S rRNA) sequencing.19,20 However, our Firmicutes: 
Bacteroidetes result is challenged by other studies where 
16S rRNA sequencing demonstrates the exact opposite 
balance in IBS,21–23 or no distinct IBS profile.24 Factors 
such as race, regional diet, and methodology may have 
had an impact on the taxonomic profiles reported.25 
A recent review on 16S rRNA sequencing data addresses 
the Firmicutes:Bacteroidetes schism, as well as the ques-
tion of diversity, concluding that most data sets support 
the increased Firmicutes:Bacteroidetes ratio in IBS, while 
a lower alpha diversity is a more prevalent finding in 
IBS.26 Further support for the hypothesis that microbiota 
composition may be a key feature in IBS pathophysiol-
ogy can be drawn from our longitudinal data showing 
increasing relative abundance of Bacteroidetes, and 
decreasing relative abundance of Firmicutes during the 
time course of the study. Thus, the microbiome profile 
change mirrors the clinical effect observed after FMT.
Moreover, the present data set showed that, based on 
taxonomic data, the short-chain fatty acid (SCFA) pro-
ducing species such as Ruminococcus sp. and 
Bifidobacterium sp.27 increased after FMT in the Effect 
group. This fits well with the notion of lower SCFA in 
IBS patients, as reviewed by Camilleri.28
The abundance of Akkermansia muciniphila was sig-
nificantly reduced at 12 months after FMT, a signal also 
reported in a recent case series.29 This species is known 
to have various effects on host T-cell immunology in 
mice, 30 and has been linked to a decrease in the integrity 
of the intestinal mucus layer.9 Furthermore, it has been 
shown to be among the five taxa associated with the 
production of 10% of fecal metabolites.31
Growth rate analysis
In the Effect group at baseline, the heat map plot 
(Figure 4(a)) shows relatively poor growth rate for 
Figure 5. Differential abundance of functional subsystems with absolute abundance > 0.01% in the Effect group, 12 months vs. 
baseline. Positive log2FC indicate enriched subsystems after FMT, negative log2FC indicate decreased subsystems after FMT. 
Subsystem level 3 indicated on the X-axis are color-coded according to level 1 classification. FDR cut off for inclusion in the plot 
was < 0.05.
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a series of Bacteroidetes species which are more 
active in the Donor feces, combined with a pattern 
of higher growth rates for a series of other species 
that are not active in the Donor group. At 
12 months, however, the resulting growth rate pat-
tern is a conglomerate of these two patterns. The 
recipients seem to have a combination of their own 
initial microbiome and the Donor microbiome, as 
also shown by both the taxonomic and functional 
OPLS analyses (Figures 3 and 6). To our knowl-
edge, the only published data on imputed growth 
rates that are somewhat comparable to this study 
found a decreased growth rate of Roseburia hominis 
when comparing IBS to healthy controls.11 This 
signal could not be found in our data, possibly 
due to a different study design (repeated measure-
ments vs. case-control). For the No effect group, 
a similar pattern of combined growth rate profiles 
could be seen, though involving much fewer bac-
terial species, and possibly leaving the overall 
impact on the recipient microbiome too weak to 
induce a clinical effect.
Functional analysis
The involvement of certain functional subsystems 
raises interesting questions about the basic 
Figure 6. Multivariate regression analysis of the functional groups. Each sample was labeled according to the corresponding study 
group. Panel A: This t1/t2-score plot of the orthogonal partial least squares projection to latent structures (OPLS) model (one predictive 
component and one orthogonal component) was built from functional groups in stool samples taken from the Donors, and from the 
Effect group at 3 time points: baseline, 6, and 12 months after FMT. The performance parameters R2Xcum, R2Ycum and Q2cum were 
0.55, 0.52 and 0.30, respectively. Panel B: The top 50 functional groups ranked by regression coefficients pertaining to the predictive 
components. To make the coefficients readily comparable, the independent variables for different functional groups were scaled and 
centered prior to the analysis. The error bars indicate the confidence intervals of the coefficients. The coefficient is considered 
significant (above noise level), when the confidence interval does not include zero. Significant features are color-coded according to 
level 1 classification.
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pathophysiology of IBS. When we consider the role 
of a FODMAP-reduced diet in IBS treatment, 
SCFA and carbohydrate signals are of special inter-
est. FODMAPs are a group of short-chain carbohy-
drates hypothesized to induce symptoms, possibly 
by altered colonic fermentation of these com-
pounds, leading to a change in the functional out-
put, which then induces gut symptoms.6,8 A recent 
study found reduced levels of inflammatory cyto-
kines, an altered gut microbiota profile, and 
reduced levels of short-chain fatty acids to be asso-
ciated with symptom relief from a low-FODMAP 
diet.32 Here, we can demonstrate that relative to 
Donor stool, the fecal samples from IBS patients 
have a lower representation of carbohydrate- 
related subsystems. In the Effect group, increases 
in D-Galacturonate and D-Glucuronate utilization, 
D-ribose utilization, L-rhamnose utilization, and 
Lactose and Galactose uptake and utilization were 
observed after 12 months. The L-rhamnose path-
way was recently reported to be among the top five 
microbial pathways associated with 53% of fecal 
metabolites found in 479 unrelated individuals.31 
Thus, the functional output of our FMT treatment 
closes the gap to the Donor profile in the Effect 
group. This change is not seen in the No effect 
group. All other subsystem clusters show 
a tendency of convergence toward the Donor profile 
in both the Effect and No effect groups.
SCFA
Strains that are known SCFA producers were rela-
tively poorly represented in the baseline samples, 
a finding also reported by Pozuelo et al. .23 On the 
functional level, the Acetyl-CoA fermentation 
pathway leading to production of the short-chain 
fatty acid butyrate33 was reduced at baseline.
Micronutrients and growth factors
The observed increase in menaquinone pathways 
after FMT has interesting implications for growth 
patterns, and for the bacterial environment, as 
menaquinones represent a major class of growth 
factors for several bacterial species in the human 
gut.34 Also, the functional subsystem involved in 
synthesis of folate was significantly more abundant, 
which is thought to enhance the growth of com-
mensals such as Lactobacillus sp.35 Subsystems 
involved in inorganic sulfur assimilation, 36 
transport of Zinc, Manganese,37 and uptake of 
heme also changed significantly after FMT. The 
acquisition of metal ions is an essential survival 
factor for all microorganisms, both in the general 
environment and in the human host.38
Strengths and weaknesses
The strengths of this study are: Firstly, our study 
design allowed microbiome analysis in two dimen-
sions: Comparison between donor and IBS, and 
over time after the FMT intervention enabling 
both the generation of an “IBS profile,” and 
a proof of concept that microbiome changes mirror 
symptom improvement. Secondly, deep metage-
nomic sequencing enables an analysis of both tax-
onomy and functional features of the microbiome, 
yielding a better understanding of these compo-
nents in IBS pathophysiology. There are also some 
weaknesses to be addressed: The sample size is 
quite small, which reduces the statistical power of 
the analyses. Also, the exploratory nature of the 
study precludes any firm conclusions. Importantly 
the transient freezer failure (mentioned in 
Materials and Methods) may have induced changes 
in the microbiome profiles, as reported by Tedjo 
et al.39 However, the temperature rise was relatively 
short and affected all samples in a similar manner. 
Thus, the observed systematic changes in the reci-
pient groups probably reflect a genuine shift. 
Further, the observed shift of microbial profile 
might also reflect changes in diet, which is known 
to affect the bacterial composition almost on a daily 
basis. However, diet registrations in the clinical 
study did not reveal any systematic changes in 
FODMAP intake during the course of the study, 
although these were only registered at two time- 
points. Our microbiome characterization only 
addresses the luminal microbiota, whereas mucosa- 
associated microbes may be quite important (16). 
We included non-constipated IBS patients with 
a broad age and BMI span in order to retain 
a high clinical translation value for the results. 
However, in the present data set, this may intro-
duce added complexity to the results due to hor-
monal effects and weight-related differences in the 
gut microbiome. Finally, the clinical study used 
only two donors, resulting in a very tight clustering 
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of the Donor samples. This is unlikely to reflect the 
actual variability found in “normal” microbiomes.
Conclusions
In conclusion, we have found distinct differences in 
microbiome composition between IBS patients and 
controls (Donors). Subjects who experienced symp-
tom relief after FMT showed a more explicit con-
vergence toward the Donor sample profiles when 
compared to subjects who had no effect of the 
intervention. This supports the hypothesis that 
intestinal dysbiosis is a key component in IBS 
pathophysiology, as well as the notion that FMT 
could be a possible treatment for IBS.
Materials and methods
Clinical study
The REFIT study was described in detail in the pri-
mary publication.15 In short, we performed a double- 
blind, randomized, placebo-controlled, parallel-group, 
single-center study. Included participants had IBS-D 
or IBS-M as defined by the ROME III criteria, were 
between 18 and 75 years old, and scored moderately to 
severely according to the IBS severity scoring system 
(IBS-SSS; score ≥175). We randomly assigned partici-
pants to active or placebo FMT (2:1). The transplant 
was either freshly processed and used the same day, or 
previously stored in a freezer. Each participant’s own 
feces served as placebo. A dose of 8 mg loperamide 
was administered orally 2 h before endoscopy, to help 
participants retain the transplant. The transplant (50–-
80 g of feces mixed with 200 mL of isotonic saline and 
50 mL of 85% glycerol) was administered to the 
cecum by colonoscope. The primary endpoint was 
a symptom relief of more than 75 points, as assessed 
by IBS-SSS, 3 months after FMT. Stool samples were 
collected from Donors at baseline, and from partici-
pants at baseline and after 6 and 12 months.
Sequencing
All samples were frozen without additives in 1.7 mL 
Eppendorf tubes at −40°C. At one point during 
storage, the freezer had a technical failure, during 
which the temperature of the samples may have 
briefly exceeded 0°C (duration ≤12 h).
Sequencing was performed at the Genomics 
Support Center Tromsø (GSCT) at UiT the Arctic 
University of Norway. DNA isolation was per-
formed on a QIAcube instrument (QIAgen, 
Hilden, Germany) using a QIAamp Fast DNA 
Stool Mini Kit (QIAgen). DNA concentration was 
measured on a Qubit 3 instrument (Thermo-Fisher, 
Massachusetts, USA). Library preparation was done 
with Nextera XT DNA library kit (Illumina, USA) 
using an input of 1 ng DNA. The samples were then 
sequenced on an Illumina NextSeq550 instrument 
with a NextSeq 500/550 High output v2 kit (300 
cycles) (Illumina), generating 2*150 base-pair 
reads. The sequencing generated a mean of 27 271 
415 (range 2 933 179 − 74 426 851) reads per sample.
In silico analysis
Pre-processing
The quality of the sequence data was investigated 
using FastQC, 40 and the data were filtered using the 
default settings for AfterQC, 41 with additional trim-
ming of the 15 first nucleotides of each read. Optical 
sequence duplicates were removed with the optical 
distance of 40 using Clumpify.42 Fastq Screen40 was 
used, together with the human genome (GRCh38), 
to filter host contamination. The unsynchronized 
PE sequence files were repaired using Repair.42
Taxonomic profiling
Taxonomic assignments of the pre-processed 
sequence reads were performed using Kaiju version 
1.6.243 against the pre-indexed NCBI BLAST nr, 
including fungi and microbial eukaryotes as refer-
ence database, and with the Greedy mode (higher 
sensitivity but longer run-time) and default para-
meter settings. The taxonomic abundance data 
from each sample – as generated by the Kaiju 
classification of the sequence reads – were merged 
into an abundance matrix and imported into 
Phyloseq44 along with the corresponding metadata.
Functional profiling
Functional assignments of the pre-processed 
sequence reads were performed using SUPER- 
FOCUS version 0.32,45 aligning reads against the 
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pre-indexed DB_98 database with DIAMOND 
0.9.14.46 The functional classification results 
obtained for each SEED (a categorization system 
which organizes gene functional categories into 
a hierarchy with five levels of resolution) subsystem 
level were imported into Phyloseq, and the prune_-
taxa function was applied to retain only subsystems 
with absolute abundance >0.01%. The data were 
transformed into fractional abundances for multi-
variate analysis and visualization in STAMP.47 
Differential abundance analysis of the SEED subsys-
tems between groups was calculated using DESeq2.48 
Only functional subsystems with differential abun-
dance at a cut off log2 fold change (FC) >0.5, and 
adjusted p-value (FDR) ≤0.05 were reported.
Statistical analysis
The species diversity (alpha diversity) in all samples 
was explored for absolute abundance values, using 
observed taxa, Chao1, Shannon, and Simpson indexes, 
and plots were generated using the plot_richness func-
tion. Taxa not seen more than five times in at least 20% 
of the samples – in the total dataset – were removed 
using the filter_taxa function. Differential abundance 
analysis between samples from participants who 
responded to treatment after 12 months, and the 
corresponding baseline samples, was performed on 
the taxa remaining after abundance filtering the data 
with DESeq2.48 Differentially abundant species were 
identified at a log2FC cut off of <-2 to >2, and an FDR 
cutoff of <10−4.
The filtered abundance data were transformed to 
fractional abundances, and only taxa with a mean frac-
tional abundance >10−5 were used. The inter-individual 
differences (beta diversity) were calculated using the 
Bray–Curtis dissimilarity index on relative abundance 
values and explored using nMDS ordination plots gen-
erated by the Phyloseq package in R. The taxa remaining 
after abundance filtering were agglomerated at each 
taxonomic rank, using the tax_glom function to gener-
ate taxonomic bar plots, and subjected to multivariate 
analysis. Finally, relative abundance plots were gener-
ated, using the filtered data, for phyla at a cut off >0.01 
relative abundance per sample group.
Regression analysis
The data were log transformed and Pareto 
scaled. Multivariate analysis was carried out 
using SIMCA software (version 15.0.2. 5559; 
Sartorius AB, Umeå, Sweden). Supervised ortho-
gonal partial least squares projection to latent 
structures (OPLS) was applied, to facilitate the 
interpretation of changes in the composition of 
bacterial species and functional group profiles 
along the time points (baseline, 6, and 
12 months). The performance of the OPLS mod-
els was described by R2Xcum, R2Ycum, and Q2cum, 
where R2Xcum is the cumulative modeled varia-
tion in X. R2Ycum is the amount of variation in 
X correlated to Y (response matrix), and Q2 cum 
is the cumulative predicted ability of the model. 
The validity and degree of overfitting of the 
OPLS models were assessed by conducting ana-
lysis of variance testing of cross-validated pre-
dictive residuals (CV-ANOVA). An obtained 
P-value lower than 0.05 was considered as an 
indication of a significant model. Variables 
were ranked according to their scaled regression 
coefficients from the OPLS models.
Growth rate analysis
To calculate the growth rate of species identified in the 
samples, GRiD18 was run. The samples were mapped 
against the stool-specific database49 using a minimum 
genome coverage cutoff = 0.2, enabling reassignment 
of ambiguous reads using Pathoscope2.50 In total, this 
analysis reported 959 species for the 47 samples. 
Species that occurred <15 times in <30 samples were 
eliminated from the further analysis, that was carried 
out on the remaining 340 species. Statistical testing on 
the ratios produced by GRiD for each species, per 
sample, was performed using ANOVA, and the results 
were visualized in STAMP.47 Only species at FDR cut 
off <0.00005 were included (n = 29) in the heat map.
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